Lucerastat, an oral therapy for Fabry disease: results from a pivotal randomized phase 3 study and its open-label extension

Journal:

Nature Communications

Published:

2026-01-10

DOI:

10.1038/s41467-025-68256-5

Affiliations:

22

Authors:

22

Go to article

Institutions	Authors	Share
Idorsia, Switzerland	6.000000	0.27
University Hospital of Würzburg (UKW), JMU, Germany	2.000000	0.09
Lysosomal and Rare Disorders Research and Treatment Center, United States of America (USA)	1.000000	0.05
University of Iowa Health Care, United States of America (USA)	1.000000	0.05
Hospital Quirónsalud Zaragoza, Spain	1.000000	0.05
Northern Care Alliance NHS Foundation Trust, United Kingdom (UK)	1.000000	0.05
UC Irvine Health, United States of America (USA)	1.000000	0.05
Baylor Scott & White Health, United States of America (USA)	1.000000	0.05
Royal Perth Hospital, Australia	1.000000	0.05
Children's Memorial Health Institute (CMHI), Poland	1.000000	0.05
The University of Alabama at Birmingham (UAB), United States of America (USA)	1.000000	0.05
Dalhousie University, Canada	1.000000	0.05
Endo-ERN - France, France	0.500000	0.02
University of Versailles Saint-Quentin-en-Yvelines (UVSQ), France	0.500000	0.02
Royal Melbourne Hospital (RMH), Australia	0.500000	0.02
The University of Melbourne (UniMelb), Australia	0.500000	0.02
University of Montreal (UdeM), Canada	0.500000	0.02
Children's Hospital Research Institute of Manitoba (CHRIM), Canada	0.500000	0.02
UCL, United Kingdom (UK)	0.500000	0.02
Royal Free London NHS Foundation Trust, United Kingdom (UK)	0.500000	0.02

Interested in Medicinal and Biomolecular Chemistry?